Urotensin II in Chronic Kidney Diseases and Kidney Transplants
NCT ID: NCT01098799
Last Updated: 2013-06-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
110 participants
OBSERVATIONAL
2010-04-30
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Low Sirtuin-1 Levels Are Linked to Erythropoietin Resistance in Hemodialysis Patients.
NCT06877286
Dcr3 Levels in Blood and Urine on Renal and Patient Prognosis in Patients With Acute Kidney Injury
NCT05735093
Emergency Department Management of Patients With Renal Infarction
NCT06515379
Tryptophan Metabolism in Kidney Disease
NCT00758537
Evaluation of s100β, NSE and GFAP Levels in Renal Transplantation
NCT04042272
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Healthy controls
No interventions assigned to this group
Chronic kidney disease-1
Chronic kidney disease not taking dialysis treatment
No interventions assigned to this group
Kidney Transplant
Kidney transplants
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
90 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Vakif Gureba Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mehmet Hursitoglu
Chair
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tufan Tukek, MD
Role: STUDY_DIRECTOR
Vakif Gureba Training & Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vakif Gureba Training & Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Dahiliye-2-Urotensin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.